AboutKaryl Kopaskie, PhD

Karyl applies her research and strategy expertise to leading the women’s health and pediatrics team, while working closely with her clinical and business counterparts. She is a thought leader specializing in service line strategy and program development, as well as key trends impacting women’s and children’s services.

Collaborating with Sg2’s service line experts across all service lines, Karyl helps clients craft their organizational definition of women’s health, from traditional obstetrics and gynecology services to comprehensive gender-specific medicine programs. She also works closely with children’s hospitals, developing enterprise strategies specific to pediatrics, as well as closely following clinical research that drives Sg2’s pediatrics forecast. Karyl challenges organizations to develop evidence-based and data-driven plans by either presenting market-specific strategic opportunities to individual clients or by generating original content on important industry trends for Sg2’s webinars and publications. In addition to her role as women’s health and pediatrics lead, Karyl also contributes to the development of Sg2’s proprietary Impact of Change® forecasting engine, which projects 10-year patient demand across inpatient and outpatient services, focusing most recently on the Hyperlocalization enhancement.

Prior to joining Sg2, Karyl worked with an early stage biotech start-up to develop a market strategy for a microbial air sampler by performing primary research and researching content for investor pitches.

Karyl earned a PhD in microbiology and an AB in physics from the University of Chicago and is an active member of the University of Chicago alumni community. She also volunteers for Pets Are Worth Saving (PAWS), an organization that strives to improve animal welfare and reduce the homeless animal population through a network of no-kill shelters.

"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube